JPRN-UMIN000022756Not yet recruiting未知
Multicenter randamized study for evaluating the effect of dantrolene aganst heart failure and arrhythmia - Dantrolene heart failure study
Yamaguchi University Graduate School of Medicine0 sites100 target enrollmentStarted: June 15, 2016Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 85years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)severe COPD 2)GM 3)severe liver dydfunction 4)ileus
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A multi-centre randomised study to evaluate the efficacy of Betaferon-interferon-beta-1b (IFNB-1B) 500 mcg therapy in the induction of tolerance to IFNB in MS patients with neutralising antibodies (NAbs) to IFNB-1a (Rebif) - Betaferon NaB Anergy StudyMultiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system of unknown aetiology. It is the commonest cause of disability in young adults. The prevalence in the UK is approximately 125/100,000 of the population with an annual incidence of 6/100,000. Approximately 80,000 individuals are affected with MS in the UK.EUCTR2005-005751-18-GBCL Biomedicine R&D Unit100
Active, not recruiting
Phase 1
Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasisPlaque psoriasisEUCTR2015-002423-26-SEovartis Pharma Services AG196
Active, not recruiting
Phase 1
Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasisPlaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858EUCTR2015-002423-26-EEovartis Pharma Services AG196
Withdrawn
Phase 4
A randomized, multicenter Study to evaluate the Effect of secukinumab 300 mg s.c. administered during 52 Weeks to patients suffering from new-onset moderate to severe plaque Psoriasis as early Intervention compared to standard treatment with narrow band UVB (STEPin study)plaque psoriasispsoriasis vulgaris10014982NL-OMON43019TFS Trial Form Support BV20
Active, not recruiting
Phase 1
Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasisPlaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858EUCTR2015-002423-26-FIovartis Pharma Services AG196